We found 28/66 (42.4%) patients positive for CK-19, 14/66 (21.2%) positive for MAGE-A3, 9/66 (13.6%) positive for HER-2, 28/66 (42.4%) positive for TWIST1, 7/66 (10.2%) positive for hTERT α+β+ and 9/66 (13.6%) positive for hMAM. In early breast cancer, the percentage of double positives for epithelial marker CK-19 and mesenchymal marker TWIST1 is 14/66 (21.2%). The gene discussed is ERBB2; the disease is breast carcinoma.